Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Non-Current Assets (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Non-Current Assets for 7 consecutive years, with $871.6 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 86.33% to $871.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 billion through Dec 2025, up 44.71% year-over-year, with the annual reading at $871.6 million for FY2025, 86.33% up from the prior year.
  • Non-Current Assets for Q4 2025 was $871.6 million at Kymera Therapeutics, up from $573.7 million in the prior quarter.
  • The five-year high for Non-Current Assets was $871.6 million in Q4 2025, with the low at $69.6 million in Q2 2021.
  • Average Non-Current Assets over 5 years is $280.2 million, with a median of $190.1 million recorded in 2022.
  • The sharpest move saw Non-Current Assets plummeted 52.99% in 2021, then soared 174.44% in 2024.
  • Over 5 years, Non-Current Assets stood at $154.6 million in 2021, then increased by 18.81% to $183.7 million in 2022, then decreased by 7.23% to $170.4 million in 2023, then skyrocketed by 174.44% to $467.8 million in 2024, then soared by 86.33% to $871.6 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $871.6 million, $573.7 million, and $402.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.